Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Notice of Proposed Sale · 144

Royalty Pharma plc

RPRXNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Aug 18, 2026Accepted Aug 18, 2026, 4:45 PM EDTFiling CIK 1802768Accession 0001628280-26-057721
Share

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer
Royalty Pharma PLC
Issuer CIK
0001802768
SEC file number
001-39329
Phone
212-883-0200
Person for whose account securities are to be sold
SCH Investment Partners LLC
Relationships to issuer
Officer
Street
110 East 59th Street
City
New York
State / country code
NY
Postal code
10022

Securities proposed for sale

Securities proposed for sale · 1 reported row
SecurityProposed unitsAggregate market valueUnits outstandingApproximate sale dateExchangeBroker / market maker
Class A Ordinary Shares100,0006,012,000445,277,34408/18/2026NASDAQMerrill Lynch

Broker / market maker — proposed row 1, entry 1

Name
Merrill Lynch
Street
One Byrant Park
City
New York
State / country code
NY
Postal code
10036

Acquisition of securities to be sold

Acquisition of securities to be sold · 2 reported rows
SecurityAcquiredNature of acquisitionAcquired fromAmount acquiredGift transactionPayment dateNature of payment
Class A Ordinary Shares02/14/2025Acquired from issuer in private transactionIssuer75,000N02/14/2025N/A
Class A Ordinary Shares05/13/2024Acquired from issuer in private transactionIssuer25,000N05/13/2024N/A

Sales reported in the preceding three months

Sales reported in the preceding three months · 2 reported rows
SellerSecuritySale dateAmount soldGross proceeds
SCH Investment Partners LLCClass A Ordinary Shares06/23/2026150,0008,166,766.13
SCH Investment Partners LLCClass A Ordinary Shares06/30/2026100,0005,645,700.97

Seller — prior-sale row 1, entry 1

Name
SCH Investment Partners LLC
Street
110 E 59th Street
City
New York
State / country code
NY
Postal code
10022

Seller — prior-sale row 2, entry 1

Name
SCH Investment Partners LLC
Street
110 E 59th Street
City
New York
State / country code
NY
Postal code
10022

Prior-sale reporting

Nothing to report for the preceding three months
N

Remarks

The sales of shares set forth herein are made in connection with a selling plan dated 03/20/2026, which is intended to comply with Rule 10b5-1(c).

Notice signature

Notice date
08/18/2026
Signed
Christopher Hite
Plan adoption dates
03/20/2026

Company context

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 16 development-stage product candidates. For more information, visit www.royaltypharma.com.

Current securities

Recent company filings

  1. 144 filingNov 17, 2026
  2. 13F-NT filingNov 13, 2026
  3. 4 filingNov 6, 2026
  4. SCHEDULE 13G/A - filed by FMR LLC regarding Royalty Pharma plcNov 5, 2026
  5. 10-Q filingNov 4, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.